Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

E. R. Petersen*, C. Ammitzbøll, H. B. Søndergaard, A. B. Oturai, P. S. Sørensen, A. C. Nilsson, L. Börnsen, M. von Essen, F. Sellebjerg

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

9 Citations (Scopus)

Abstract

The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

Original languageEnglish
Article number577085
JournalJournal of Neuroimmunology
Volume337
ISSN0165-5728
DOIs
Publication statusPublished - 2019

Keywords

  • Adhesion molecules
  • ALCAM
  • Blood-brain barrier
  • MCAM-1
  • Multiple sclerosis
  • Natalizumab

Cite this